UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of October 2013
000-55041
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____
On October 31, 2013, Can-Fite BioPharma Ltd. (the “Company”) filed in Israel an investor presentation titled “Can-Fite Investor Presentation – Fall 2013” with respect to the Company’s business and uploaded a copy of the same to the Company’s website at www.canfite.com. A copy of such investor presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit Index
Exhibit No. |
Description | |
99.1 | Can-Fite Investor Presentation – Fall 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Can-Fite BioPharma Ltd. | ||
Date: October 31, 2013 | By: | /s/ Motti Farbstein |
Motti Farbstein Chief Operating and Financial Officer |